论文部分内容阅读
目的比较分析信必可与普米克联合奥克斯都保治疗哮喘患者的依从性与哮喘症状复发的关系。方法选择门诊哮喘患者83例,其中吸入信必可都保41例和使用普米克+奥克斯都保42例,门诊复诊或电话随访进行两种治疗依从性的调查。结果信必可组完全遵从医嘱用药者21例,依从率为51.2%,不同程度的未遵从医嘱用药(依从性不佳)者20例占48.8%,两者哮喘症状复发率分别为19.1%和45.0%;普米克+奥克斯都保组完全遵从医嘱者16例,依从率为38.1%,依从性不佳者61.9%,两者哮喘症状复发率分别为18.8%和53.8%,两组内复发率比较差异有显著性(P<0.05),组间复发率比较差异无显著性(P>0.05)。结论信必可都保和普米克+奥克斯都保联合用药治疗哮喘患者的依从性有差异,信必可都保治疗组依从性更好,治疗依从性不佳是哮喘症状复发、病情控制不理想的重要原因之一。
OBJECTIVE: To compare the relationship between the compliance of Xinbi and Pulmicort and Oxmax in the treatment of asthma patients and the relapse of asthma symptoms. Methods Eighty-three outpatients with asthma were selected. Among them, 41 cases were inhaled letters, 42 cases were used for insipidation, 42 cases were treated with Pulmicort and Oaks, and follow-up visits were followed up for follow-up survey. Results 21 cases were believed to be completely complied with the prescribed medication, the compliance rate was 51.2%, 20 cases were 48.8% with varying degrees of non-compliance (19.1%), and the recurrence rate of asthma symptoms were 19.1% 45.0%; Pulmicort + Oaks DuPont fully comply with the order of 16 patients, the compliance rate was 38.1%, 61.9% of the poor compliance, both the recurrence rate of asthma symptoms were 18.8% and 53.8%, the recurrence rate within the two groups The difference was significant (P <0.05). There was no significant difference in the recurrence rate between groups (P> 0.05). CONCLUSIONS: The compliance of patients with asthma treated with combination of bcl-2 and omex-dicobarbital was different, and the compliance with the letter-and-cure group was better and the poor compliance was the recurrence of asthma and the unsatisfactory condition control One of the important reasons.